 |
| Package Specification: | |
|---|---|
| Quantity: | |
Bioteke
B. Detection Principle
Neuron specific enolase (NSE) is one of the enolases involved in the glycolytic pathway, present in neural and neuroendocrine tissues.
This kit is an immunochromatographic kit that uses a double antibody sandwich method to detect AFP in human blood samples.
C. Clinical Significance
High concentrations exist in nerve cells, neuroendocrine cells, and tumor cells caused by these cells:
1. Bronchial cancer:
NSE is considered the preferred biomarker for detecting small cell bronchial cancer, with 60% -81% of cases showing elevated NSE concentrations. The concentration of NSE briefly increases 24-72 hours after the start of the first chemotherapy cycle, and can last for one week or rapidly decrease at the end of the first chemotherapy cycle (with an increase in pre-treatment concentration). On the contrary, patients who do not respond to chemotherapy will have a sustained increase or no decrease in NSE concentration within the reference range. During the period of remission, 80-96% of patients have normal NSE concentration, while NSE concentration increases when the condition recurs. NSE can be used to evaluate the prognosis, treatment effectiveness, and related etiology of small cell lung cancer patients: diagnostic sensitivity of 93%, positive predictive value of 92%.
2. Neuroblastoma:
Neuroblastoma is a common solid tumor in children, originating from the spinal cord and often difficult to diagnose accurately.
3. Other tumors:
In clinical practice, 68% -73% of patients with seminomas have significantly increased NSE concentrations, which are practically correlated with the clinical disease process. 22% of non malignant lung diseases (regardless of tumor stage) have NSE concentrations higher than 25ng/mL. Patients with brain tumors such as gliomas, spinal cord tumors, neurofibromas, and neuromas may occasionally have elevated levels of NSE.
4. Benign diseases:
Patients with benign lung and brain diseases may also have elevated serum NSE concentrations (>12ng/mL), such as diffuse encephalitis, spinal cord and cerebellar degeneration, cerebral ischemia, cerebral infarction, intracranial blood clots, traumatic brain injury, schizophrenia, etc.
D. Package Components
(1 Test/Kit)
Specimen: Serum/Plasma/Whole Blood
Please refer to the User Manual for the test process.
Note:
1. Before testing, please carefully read these usage instructions. Only by following all instructions correctly can testing be reliable.
2. Ensure that the sample loading is appropriate, as results of excessive or insufficient sample loading may be unreliable.
3. The test results of this reagent kit are for clinical reference only. Doctors should make a final diagnosis by combining various test results and clinical symptoms.
4. The result may be interfered by HAAA (human anti animal antibody), heterophilic antibody, self analyte antibody, rheumatoid factor, and other proteins such as hormone binding proteins in the blood of patient.
E. Storage Conditions and Shelf Life
1. Storage Condition: A dry and dark place at 2-30 ℃.
2. Shelf Life: 2 years and should not be frozen.
3.The reagent should be used as soon as possible within 1 hour after opening the aluminum foil bag.
When the ambient temperature is above 30 ℃ or the humidity is high, it is recommended to use the reagent as soon as possible.
B. Detection Principle
Neuron specific enolase (NSE) is one of the enolases involved in the glycolytic pathway, present in neural and neuroendocrine tissues.
This kit is an immunochromatographic kit that uses a double antibody sandwich method to detect AFP in human blood samples.
C. Clinical Significance
High concentrations exist in nerve cells, neuroendocrine cells, and tumor cells caused by these cells:
1. Bronchial cancer:
NSE is considered the preferred biomarker for detecting small cell bronchial cancer, with 60% -81% of cases showing elevated NSE concentrations. The concentration of NSE briefly increases 24-72 hours after the start of the first chemotherapy cycle, and can last for one week or rapidly decrease at the end of the first chemotherapy cycle (with an increase in pre-treatment concentration). On the contrary, patients who do not respond to chemotherapy will have a sustained increase or no decrease in NSE concentration within the reference range. During the period of remission, 80-96% of patients have normal NSE concentration, while NSE concentration increases when the condition recurs. NSE can be used to evaluate the prognosis, treatment effectiveness, and related etiology of small cell lung cancer patients: diagnostic sensitivity of 93%, positive predictive value of 92%.
2. Neuroblastoma:
Neuroblastoma is a common solid tumor in children, originating from the spinal cord and often difficult to diagnose accurately.
3. Other tumors:
In clinical practice, 68% -73% of patients with seminomas have significantly increased NSE concentrations, which are practically correlated with the clinical disease process. 22% of non malignant lung diseases (regardless of tumor stage) have NSE concentrations higher than 25ng/mL. Patients with brain tumors such as gliomas, spinal cord tumors, neurofibromas, and neuromas may occasionally have elevated levels of NSE.
4. Benign diseases:
Patients with benign lung and brain diseases may also have elevated serum NSE concentrations (>12ng/mL), such as diffuse encephalitis, spinal cord and cerebellar degeneration, cerebral ischemia, cerebral infarction, intracranial blood clots, traumatic brain injury, schizophrenia, etc.
D. Package Components
(1 Test/Kit)
Specimen: Serum/Plasma/Whole Blood
Please refer to the User Manual for the test process.
Note:
1. Before testing, please carefully read these usage instructions. Only by following all instructions correctly can testing be reliable.
2. Ensure that the sample loading is appropriate, as results of excessive or insufficient sample loading may be unreliable.
3. The test results of this reagent kit are for clinical reference only. Doctors should make a final diagnosis by combining various test results and clinical symptoms.
4. The result may be interfered by HAAA (human anti animal antibody), heterophilic antibody, self analyte antibody, rheumatoid factor, and other proteins such as hormone binding proteins in the blood of patient.
E. Storage Conditions and Shelf Life
1. Storage Condition: A dry and dark place at 2-30 ℃.
2. Shelf Life: 2 years and should not be frozen.
3.The reagent should be used as soon as possible within 1 hour after opening the aluminum foil bag.
When the ambient temperature is above 30 ℃ or the humidity is high, it is recommended to use the reagent as soon as possible.
